Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


ASH 2022: Early-Phase Trial Evaluates Elranatamab in Resistant Multiple Myeloma

By: Vanessa A. Carter, BS
Posted: Monday, December 12, 2022

Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, and colleagues assessed the efficacy and safety of elranatamab—a B-cell maturation antigen (BCMA)-CD3 bispecific antibody—in patients with relapsed or refractory multiple myeloma. Presented during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 158), the results of this trial featured a 64% overall response rate and a measurable residual disease (MRD) negativity rate of 100%.

“Elranatamab induced durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma,” concluded the study authors. “Together with emerging data from pivotal studies MagnetisMM-3 and MagnetisMM-5, these results support further development of elranatamab for patients with multiple myeloma.”

The investigators focused on 55 patients with relapsed or refractory multiple myeloma. Subcutaneous single-agent elranatamab was administered at doses from 80 to 1,000 µg/kg and given either weekly or every 2 weeks.

With a median follow-up of 12 months, all patients received elranatamab at a dose of at least 215 μg/kg. The objective response rate was 64%, with 56% of patients achieving a very good partial response or better and 38% demonstrating a complete response or better. Of note, 54% of patients who underwent prior BCMA-directed therapy responded, and 46% achieved a very good partial response or better.

The most common treatment-emergent adverse events included anemia, injection-site reaction, cytokine-release syndrome, lymphopenia, and neutropenia. Of note, the overall incidence of cytokine-release syndrome was 67% and was limited to grade 1 or 2 (33% each). Elranatamab exposure appeared to be dose-dependent, with cytokine increases developing with the first dose and reduced by premedication. Furthermore, with a median time to response of 36 days, soluble BCMA decreased with response, and elranatamab treatment was associated with increased peripheral T-cell proliferation.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.